Positive PhIII data with Keryx's Zerenex in hyperphosphataemia
This article was originally published in Scrip
Executive Summary
Keryx Biopharmaceuticals reported positive results in a Phase III study assessing the efficacy of Zerenex (ferric citrate) for elevated serum phosphorus levels (hyperphosphataemia) in patients with end-stage renal disease who are on dialysis.